Evidence map›Paper›PMID 41264364›Full record

ArticleThe Journal of clinical investigation2026

GDF15 is a putative biomarker for distinguishing pulmonary veno-occlusive disease and pulmonary arterial hypertension.

Amit Prabhakar, Eckart Mdd De Bie, Jacqueline T DesJardin, Prajakta Ghatpande, Stefan Gräf, Luke S Howard, S John Wort, Colin Church, David G Kiely, UK Pulmonary Arterial Hypertension Cohort Study Consortium and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Amit PrabhakarCardiovascular Research Institute, UCSF, San Francisco, California, USA.
Eckart Mdd De BieVictor Phillip Dahdaleh Heart & Lung Research Institute, University of Cambridge, Cambridge, United Kingdom.
Jacqueline T DesJardinPulmonary Vascular Disease, PAH Center of Comprehensive Care, Division of Cardiology, Department of Medicine, UCSF, San Francisco, California, USA.
Prajakta GhatpandeCardiovascular Research Institute, UCSF, San Francisco, California, USA.
Stefan GräfVictor Phillip Dahdaleh Heart & Lung Research Institute, University of Cambridge, Cambridge, United Kingdom.
Luke S HowardImperial College London Faculty of Medicine, National Heart & Lung Institute, London, United Kingdom.
S John WortImperial College London Faculty of Medicine, National Heart & Lung Institute, London, United Kingdom.
Colin ChurchGolden Jubilee National University Hospital and University of Glasgow, Glasgow, United Kingdom.
David G KielySheffield Pulmonary Vascular Disease Unit and NIHR Biomedical Research Centre, Sheffield Teaching Hospitals NHS Foundation Trust, UK and Clinical Medicine, University of Sheffield, Sheffield, United Kingdom.
UK Pulmonary Arterial Hypertension Cohort Study Consortium
Emily SumpenaPulmonary Vascular Disease, PAH Center of Comprehensive Care, Division of Cardiology, Department of Medicine, UCSF, San Francisco, California, USA.
Thin AungPulmonary Vascular Disease, PAH Center of Comprehensive Care, Division of Cardiology, Department of Medicine, UCSF, San Francisco, California, USA.
Shenrae CarterPulmonary, Critical Care, Allergy and Sleep Medicine, UCSF, San Francisco, California, USA.
Jasleen KukrejaDepartment of Cardiothoracic Surgery, UCSF, San Francisco, California, USA.
Steven HaysPulmonary, Critical Care, Allergy and Sleep Medicine, UCSF, San Francisco, California, USA.
John R GreenlandPulmonary, Critical Care, Allergy and Sleep Medicine, UCSF, San Francisco, California, USA.
Jonathan P SingerPulmonary, Critical Care, Allergy and Sleep Medicine, UCSF, San Francisco, California, USA.
Michael WaxPulmonary, Critical Care, Allergy and Sleep Medicine, UCSF, San Francisco, California, USA.
Paul J WoltersPulmonary, Critical Care, Allergy and Sleep Medicine, UCSF, San Francisco, California, USA.
Marc A SimonPulmonary Vascular Disease, PAH Center of Comprehensive Care, Division of Cardiology, Department of Medicine, UCSF, San Francisco, California, USA.
Mark ToshnerVictor Phillip Dahdaleh Heart & Lung Research Institute, University of Cambridge, Cambridge, United Kingdom.
Giorgio LagnaCardiovascular Research Institute, UCSF, San Francisco, California, USA.
Akiko HataCardiovascular Research Institute, UCSF, San Francisco, California, USA.

Funding

Elucidating the structural insights into the BMP receptor mutations in PAHR01HL164581 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Akiko Hata, Natalia Jura · 2023 to 2026
$3.1M
Molecular pathogenesis of pulmonary arterial hypertensionR01HL153915 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HATA, AKIKO · 2021 to 2024
$3.1M
NHLBI NIH HHS R01 HL153915NHLBI NIH HHS R01 HL164581
6 · The paper itself

Abstract

Study identifies GDF15 as a biomarker-accurately distinguishing PVOD from other PAH forms and predicting outcomes across PVOD, IPAH, and HPAH-advancing earlier diagnosis and personalized treatment.

Indexed as

Growth Differentiation Factor 15Pulmonary Arterial HypertensionPulmonary Veno-Occlusive DiseaseAdultBiomarkersDiagnosis, DifferentialFemaleHumansMaleBiomarkersGDF15 protein, humanGrowth Differentiation Factor 15BiomarkersCardiovascular diseaseClinical ResearchHypertensionVascular biology

Identifiers

PMID41264364
PMCPMC12807463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.